Daniel Weckbecker

MODAG aims to provide a novel approach for treating neurodegenerative diseases by combining targeted small molecule therapeutics with the right diagnostic tools. Their first objective is to demonstrate clinical proof-of-concept with their lead compound anle138b in Multiple System Atrophy (MSA) seeking to halt the progression and provide a firstdisease-modifying therapeutic.This success will allow us to apply their technology to similar diseases such as Parkinson’s and other synucleinopathies with the goal of dissolving disease-related intra-cellular oligomers, thereby reducing their toxic properties.MODAG is comprised of experts in the clinical research and neurodegenerative disease space and supported by grants from leading patient organizations including the Michael J Fox Foundation, Cure Parkinson's Trust and Parkinson’s UK.